Factor Xa Inhibitors

• 

  Subject Areas on Research

  • A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 
  • A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation. 
  • A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. 
  • A new era in secondary prevention after acute coronary syndrome. 
  • A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 
  • A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. 
  • A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. 
  • Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors. 
  • Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. 
  • Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. 
  • Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. 
  • Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. 
  • Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. 
  • Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay. 
  • Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. 
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. 
  • Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. 
  • Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. 
  • Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. 
  • Apixaban after acute coronary syndrome. 
  • Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. 
  • Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. 
  • Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. 
  • Apixaban to prevent stroke in patients with atrial fibrillation: a review. 
  • Apixaban versus warfarin in patients with atrial fibrillation. 
  • Apixaban with antiplatelet therapy after acute coronary syndrome. 
  • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. 
  • Apixaban: an emerging oral factor Xa inhibitor. 
  • Assays for measuring rivaroxaban: their suitability and limitations. 
  • Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. 
  • Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. 
  • Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. 
  • Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. 
  • CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. 
  • Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. 
  • Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? 
  • Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. 
  • Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. 
  • Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. 
  • Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. 
  • Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. 
  • Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. 
  • Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. 
  • Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. 
  • Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. 
  • Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. 
  • Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. 
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. 
  • Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies. 
  • Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. 
  • Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. 
  • Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. 
  • Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. 
  • Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. 
  • Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. 
  • Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. 
  • Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation Complications. 
  • DVT: a new era in anticoagulant therapy. 
  • Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. 
  • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 
  • Development of universal antidotes to control aptamer activity. 
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). 
  • Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. 
  • Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. 
  • Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. 
  • Early Chemoprophylaxis Against Venous Thromboembolism in Patients With Traumatic Brain Injury. 
  • Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. 
  • Edoxaban and the need for outcomes-based NOAC dosing. 
  • Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. 
  • Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. 
  • Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. 
  • Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. 
  • Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). 
  • Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. 
  • Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. 
  • Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. 
  • Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). 
  • Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. 
  • Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trial. 
  • Emergency Department Discharge of Pulmonary Embolus Patients. 
  • Emerging applications of aptamers for anticoagulation and hemostasis. 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. 
  • Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. 
  • Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). 
  • Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. 
  • FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial. 
  • Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). 
  • Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). 
  • Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. 
  • Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. 
  • Heparin-Induced Thrombocytopenia: A Focus on Thrombosis. 
  • Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. 
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. 
  • Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. 
  • Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. 
  • Incidence and Predictors of Left Atrial Appendage Thrombus in Patients Treated With Nonvitamin K Oral Anticoagulants Versus Warfarin Before Catheter Ablation for Atrial Fibrillation. 
  • Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. 
  • Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. 
  • Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. 
  • Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. 
  • Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. 
  • Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. 
  • Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation. 
  • Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials. 
  • Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. 
  • Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. 
  • Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. 
  • Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. 
  • Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. 
  • Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study. 
  • Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. 
  • Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. 
  • New anticoagulants--the path from discovery to clinical practice. 
  • New oral anticoagulant-induced bleeding: clinical presentation and management. 
  • New reversal agent for factor Xa inhibitors shows promise. 
  • Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. 
  • Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Novel constructs for thrombin inhibition. 
  • Novel oral anticoagulants and reversal agents: Considerations for clinical development. 
  • On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. 
  • Oral factor Xa inhibitors for the long-term management of ACS. 
  • Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. 
  • Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. 
  • Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. 
  • Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. 
  • Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). 
  • Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. 
  • Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization: From the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. 
  • Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. 
  • Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. 
  • Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. 
  • Preclinical differentiation of low molecular weight heparins. 
  • Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. 
  • Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. 
  • Promise of factor Xa inhibition in atrial fibrillation. 
  • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 
  • Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. 
  • Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). 
  • Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. 
  • Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. 
  • Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. 
  • Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. 
  • Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. 
  • Reexamination of the Embolic Stroke of Undetermined Source Concept. 
  • Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). 
  • Renal Dysfunction: The Wake-Up Alarm for Chronic Vascular Disease. 
  • Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. 
  • Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF". 
  • Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". 
  • Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. 
  • Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation. 
  • Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. 
  • Rivaroxaban Plus Aspirin After CABG: More Evidence Is Needed. 
  • Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. 
  • Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. 
  • Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. 
  • Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. 
  • Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. 
  • Rivaroxaban in Peripheral Artery Disease after Revascularization. 
  • Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. 
  • Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. 
  • Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. 
  • Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. 
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. 
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Road mapping ATLAS ACS 2: are we there yet? 
  • Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. 
  • Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. 
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. 
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. 
  • Should patients on vitamin K antagonists be treated differently? 
  • Sodium binding site of factor Xa: role of sodium in the prothrombinase complex. 
  • Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. 
  • Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. 
  • Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician. 
  • Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. 
  • Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. 
  • The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. 
  • The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? 
  • The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. 
  • The pharmacology of novel oral anticoagulants. 
  • The safety and efficacy of apixaban : where do we stand in 2013? 
  • The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. 
  • Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. 
  • Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. 
  • Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. 
  • To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. 
  • Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. 
  • Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. 
  • Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. 
  • Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. 
  • Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. 
  • Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. 
  • Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. 
  • Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments].